Mark C. McKenna - Mar 15, 2023 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role: Chairman, President & CEO, Director
Signature: /s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Stock symbol: RXDX
Transactions as of: Mar 15, 2023
Transactions value $: -$2,831,000
Form type: 4
Date filed: 3/17/2023, 09:02 PM
Previous filing: Mar 3, 2023
Next filing: Jun 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXDX	Common Stock	Options Exercise	$72.5K	+25K	+45.34%	$2.90^*	80.1K	Mar 15, 2023	Direct	F1
transaction	RXDX	Common Stock	Sale	-$2.9M	-25K	-31.19%	$116.14	55.1K	Mar 15, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXDX	Stock Option (Right to Buy)	Options Exercise	$0	-25K	-8.1%	$0.00	284K	Mar 15, 2023	Common Stock	25K	$2.90	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3	25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.